Comparative evaluation of the effectiveness of monotherapy of ulcerative colitis with mesalazine MMX and combination therapy with non-prolonged mesalazines with rectal forms

Abstract

Introduction. According to clinical guidelines, the treatment of patients with ulcerative colitis (UC) is carried out as combination therapy with mesalazine in rectal forms.The aim was to compare the effectiveness of treatment of moderate severity UC patients receiving mesalazine MMH as monotherapy and mesalazine in combination with mesalazine for rectal use.Materials and methods. Comparative clinical analysis of the results of treatment of patients with moderate UC receiving mesalazine MMX as monotherapy (1st group, 44 patients) and mesalazine in combination with mesalazine for rectal use (microclysters, suppositories) (2nd group, 40 patients) was performed.Results and discussion. After 2 weeks of therapy with mesalazine MMX, 95.0% of the 1st group patients responded to therapy with mesalazine MMX and continued treatment with it as monotherapy (without microclysters and suppositories). In Group 2, 97.2% of patients responded to mesalazine therapy and continued treatment with topical forms of mesalazine - microglia and suppositories. After 12 weeks, 87.5% of the 44 patients in Group 1 who responded to mesalazine MMX therapy and 88.9% of the 40 patients in Group 2 who responded to mesalazine therapy achieved clinical remission. After 52 weeks, 82.5% of 44 Group 1 patients and 86.1% of 40 Group 2 patients remained in clinical remission. The Meio index decreased from 7.9 ± 0.13 to 2.4 ± 0.4 points in group 1 and from 8.0 ± 0.17 to 2.3 ± 0.2 in group 2. There was no statistically significant difference in the level o laboratory indices between the groups after 12 and 52 weeks (p > 0.05).Conclusion. Our study confirms that continuous regular administration of MMX mesalazine as monotherapy in doses according to the clinical guidelines is comparable in its effectiveness to combined therapy with non prolonged mesalazine and topical forms of mesalazine in patients with UC of moderate severity.